Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ATACAND

« Back to Dashboard

Summary for Tradename: ATACAND

Patents:3
Applicants:1
NDAs:2
Suppliers: see list6

Pharmacology for Tradename: ATACAND

Clinical Trials for: ATACAND

CKD-330 Drug-Drug Interaction Study (Candesartan)
Status: Completed Condition: Hypertension

Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo
Status: Completed Condition: Hypertension

Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)
Status: Completed Condition: Hypertension; Left Ventricular Hypertrophy

ARIA (Atacand Renoprotection In NephropAthy Pt.)
Status: Completed Condition: Non-diabetic Nephropathy With Hypertension

Candesartan Effect in Second Stage Arterial Hypertension
Status: Completed Condition: Stage II Hypertension

Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal
Status: Completed Condition: Healthy

Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age
Status: Completed Condition: Hypertension

Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension
Status: Completed Condition: Hypertension

Pharmacokinetic Interactions of Candesartan Cilexetil and Amlodipine Besylate
Status: Active, not recruiting Condition: Healthy

Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed
Status: Completed Condition: Hypertension

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca
ATACAND HCT
candesartan cilexetil; hydrochlorothiazide
TABLET;ORAL021093Sep 5, 2000RXNo5,534,534*PED<disabled>Y<disabled>
Astrazeneca
ATACAND HCT
candesartan cilexetil; hydrochlorothiazide
TABLET;ORAL021093May 16, 2008RXYes5,534,534*PED<disabled>Y<disabled>
Astrazeneca
ATACAND
candesartan cilexetil
TABLET;ORAL020838Jun 4, 1998RXNo5,534,534*PED<disabled>Y<disabled>
Astrazeneca
ATACAND HCT
candesartan cilexetil; hydrochlorothiazide
TABLET;ORAL021093May 16, 2008RXYes5,721,263<disabled>Y<disabled>
Astrazeneca
ATACAND
candesartan cilexetil
TABLET;ORAL020838Jun 4, 1998RXYes5,534,534*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ATACAND

Drugname Dosage Strength RLD Submissiondate
candesartan cilexetil and hydrochlorothiazideTablets32 mg/25 mgAtacand HCT3/6/2009
candesartan cilexetil and hydrochlorothiazideTablets16 mg/12.5 mg and 32 mg/12.5 mgAtacand HCT6/25/2008
candesartan cilexetilTablets4 mg, 8 mg, 16 mg and 32 mgAtacand12/22/2006
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc